Know Cancer

or
forgot password

Measurement of Potential Biomarkers Predicting Erlotinib Response


N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

Measurement of Potential Biomarkers Predicting Erlotinib Response


OBJECTIVES:

- To evaluate whether serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin can
be utilized as biomarkers to predict response in patients with non-small cell lung
cancer treated with erlotinib hydrochloride.

OUTLINE: Serum samples are analyzed for NGAL, MMP-9, NGAL/MMP-9, and soluble E-cadherin by
ELISA and Luminex assays.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of non-small cell lung cancer

- Received erlotinib hydrochloride on clinical trial ECOG-E3503

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Baseline serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin levels as predictors of erlotinib hydrochloride response

Safety Issue:

No

Principal Investigator

Steven M. Dubinett, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Jonsson Comprehensive Cancer Center

Authority:

Unspecified

Study ID:

CDR0000670992

NCT ID:

NCT01123460

Start Date:

April 2010

Completion Date:

Related Keywords:

  • Lung Cancer
  • non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location